Literature DB >> 19718658

Alternative splicing of ADAM15 regulates its interactions with cellular SH3 proteins.

Iivari Kleino1, Rebekka M Ortiz, Miljamartta Yritys, Ari-Pekka J Huovila, Kalle Saksela.   

Abstract

A Disintegrin And Metalloprotease (ADAM15) is a member of the adamalysin protein family and has been associated with cancer, possibly via its role in ectodomain shedding of cadherins. Alternative mRNA splicing generates several ADAM15 isoforms containing different combinations of putative Src homology-3 (SH3) domain binding sites in their cytosolic tails. Here we present a comprehensive characterization of SH3 binding potential of different ADAM15 isoforms. Alternative use of ADAM15 exons was found to profoundly influence selection of SH3-containing cellular partner proteins, including the avid interactions with nephrocystin and sorting nexin-33 (SNX33 a.k.a. SNX30). Specifically, strong co-precipitation of nephrocystin from cell lysates was specific to ADAM15 isoforms i4, i5, and i6. These isoforms contain one or both of the two almost identical proline-rich regions encoded by exons 20 and 21, wherein the residues RxLPxxP were found to be indispensable for nephrocystin SH3 binding. Similarly, robust cellular association with SNX33 was observed only for ADAM15 isoforms containing the most carboxyterminal proline cluster lacking in isoforms i1 and i3. Thus, alternative mRNA splicing provides a versatile mechanism for regulation of intracellular protein interactions and thereby likely the cellular functions of ADAM15, which could explain the association with cancer of some but not all ADAM15 isoforms. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19718658     DOI: 10.1002/jcb.22317

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  9 in total

1.  ADAM15 protein amplifies focal adhesion kinase phosphorylation under genotoxic stress conditions.

Authors:  Dorothee Fried; Beate B Böhm; Kristin Krause; Harald Burkhardt
Journal:  J Biol Chem       Date:  2012-04-27       Impact factor: 5.157

Review 2.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

3.  Large-Scale Screening of Preferred Interactions of Human Src Homology-3 (SH3) Domains Using Native Target Proteins as Affinity Ligands.

Authors:  Arunas Kazlauskas; Constanze Schmotz; Tapio Kesti; Jussi Hepojoki; Iivari Kleino; Tomonori Kaneko; Shawn S C Li; Kalle Saksela
Journal:  Mol Cell Proteomics       Date:  2016-07-20       Impact factor: 5.911

4.  Conservation and divergence of ADAM family proteins in the Xenopus genome.

Authors:  Shuo Wei; Charles A Whittaker; Guofeng Xu; Lance C Bridges; Anoop Shah; Judith M White; Douglas W Desimone
Journal:  BMC Evol Biol       Date:  2010-07-14       Impact factor: 3.260

Review 5.  ADAM-15 disintegrin-like domain structure and function.

Authors:  Dong Lu; Mike Scully; Vijay Kakkar; Xinjie Lu
Journal:  Toxins (Basel)       Date:  2010-10-19       Impact factor: 4.546

6.  Alternative mRNA splicing generates two distinct ADAM12 prodomain variants.

Authors:  Sara Duhachek-Muggy; Hui Li; Yue Qi; Anna Zolkiewska
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

7.  Preferred SH3 domain partners of ADAM metalloproteases include shared and ADAM-specific SH3 interactions.

Authors:  Iivari Kleino; Annika Järviluoma; Jussi Hepojoki; Ari Pekka Huovila; Kalle Saksela
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

8.  ADAM15 mediates upregulation of Claudin-1 expression in breast cancer cells.

Authors:  Jens Mattern; Christian S Roghi; Melanie Hurtz; Vera Knäuper; Dylan R Edwards; Zaruhi Poghosyan
Journal:  Sci Rep       Date:  2019-08-29       Impact factor: 4.379

9.  Identification of SH3 domain proteins interacting with the cytoplasmic tail of the a disintegrin and metalloprotease 10 (ADAM10).

Authors:  Henriette Ebsen; Marcus Lettau; Dieter Kabelitz; Ottmar Janssen
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.